The talks, in Jamaica, are before the International Seabed Authority (ISA), the only organization that can legally approve ...

Developing new biomarker assays is highly specialised work. It requires careful screening of antibody pairs, sensitivity and ...

A meta-analysis of 127 studies published in Annual Review of Nutrition found that coffee can reduce your risk of cancer up to 20 percent, your risk of type 2 diabetes by 30 percent, and your risk of ...

Aviation has acknowledged many individuals who have marked the passage of time and technology to get aviation to where it is today. As a rule, these people have often done something pretty spectacular ...

The Washington, D.C.–Baltimore area ranks in the top six for life sciences R&D and manufacturing talent, according to a CBRE report. The Maryland Department of Commerce’s director of life sciences ...

A controversial arsenic microbe study unveiled 15 years ago has been retracted. The study’s authors are crying foul ...

The journal Science retracts a headline-grabbing study, but the authors vigorously defend their data and say the retraction ...

Putting this theory to the test, Quinn began what he calls the process of “AI-ifying myself.” He built a custom GPT, a ...

A controversial 2010 study that suggested bacteria could grow using arsenic instead of phosphorus has been retracted by the ...

China is racing ahead on biotech innovation, and the US could be falling behind.

When problems like this are uncovered, they can make their way into public conversations, where they are not necessarily perceived as triumphant acts of self-correction. Rather, they may be taken as ...

Investing.com - Goldman Sachs (NYSE: GS) has resumed coverage of Roivant Sciences (NASDAQ: ROIV) with a Buy rating and a price target of $19.00, according to a research note released Thursday.